Synaptic tau and synaptogyrin‐3 are promising targets to tackle tauopathies. (December 2021)

• Record Type: Journal Article
• Authors: Largo‐Barrientos, Pablo; Uytterhoeven, Valerie; de Wit, Joris; De Strooper, Bart; Verstreken, Patrik
• Is Part Of: Alzheimer's & dementia. Volume 17(2021)Supplement 3
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.054187
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Different pathogenic conditions (Alzheimer's disease and other tauopathies) induce detachment of Tau protein from microtubules. Detached Tau accumulates at synapses and binds to synaptic vesicle‐associated protein Synaptogyrin‐3, hampering vesicle mobility and neurotransmitter release (Zhou et al., Nature Communications 2017). Lowering the levels of Synaptogyrin‐3 alleviates synaptic dysfunction in fruit flies and mouse primary neurons McInnes et al., Neuron 2018). Method: We pursued two strategies to lower Synaptogyrin‐3 expression in a tauopathy mouse model (human P301S Tau‐expressing mice; "PS19 mouse line"). We generated a synaptogyrin‐3 knockout mouse usign CRISPR/Cas9 and crossed it with Tau P301S mice. In paralel, we designed several antisense oligonucleotides (ASOs) against common sequences of mouse and human Synaptogyrin‐3. Result: We showed that lowering expression of Synaptogyrin‐3 is benign in mice, but strongly rescues mutant Tau‐induced defects in long‐term synaptic plasticity and working memory. We screened several anti‐Synaptogyrin‐3 ASOs in vitro and selected the most effective one to further study its effects in vivo. Conclusion: Lowering Synaptogyrin‐3 is safe and sufficient to prevent cognitive decline in Tau P301S mice. Further research will determine the therapeutic potential of interfering with the interaction of Tau and Synaptogyrin‐3 in the context of tauopathies.